GO
Loading...

Enter multiple symbols separated by commas

Biogen Inc

More

  • --Amgen in late 2012 bought Decode Genetics for $415 million in cash to gain access to a database of complete genetic sequences of 2,636 Icelanders. --In January 2014, Regeneron Pharmaceuticals Inc signed a deal with Geisinger Health System in Pennsylvania to sequence DNA from as many as 250,000 volunteers from Geisinger's pool of 3 million patients.

  • Regeneron Pharmaceuticals Inc, which signed a deal with Pennsylvania's Geisinger Health System in January 2014 to sequence partial genomes of some 250,000 volunteers, is already claiming discoveries based on the new approach. Pfizer Inc, Roche Holding AG and Biogen Inc are working on similar projects that use DNA and patient health data to find new drug...

  • Early movers: AOL, WHR, PM, CBS, NOK & more Friday, 8 May 2015 | 7:47 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Biotech bust may be sending message about stocks Thursday, 30 Apr 2015 | 5:03 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Traders are watching the iShares Nasdaq Biotechnology ETF for clues on whether a deeper stock market decline is on the horizon.

  • Pisani: Stay calm, despite poor end to the month Thursday, 30 Apr 2015 | 4:59 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Crowded "long" trades unwinding

  • Biotech's boom fuels real estate here Thursday, 30 Apr 2015 | 12:11 PM ET
    Signage sits on display in an atrium at Genzyme Corp.'s headquarters in Cambridge, Massachusetts.

    As biotech has boomed over the last few years, so has real estate in Kendall Square in Cambridge, Massachusetts.

  • Street picks: 10 stocks ready to pop Thursday, 30 Apr 2015 | 7:00 AM ET

    More than half of the S&P 500 is projected to rise by 8 percent in 12 months, according to analysts. Here are the stocks that could rise the most.

  • Biogen takes on Alzheimer's   Tuesday, 28 Apr 2015 | 4:29 PM ET
    alzheimer's

    George Scangos, Biogen CEO, discusses progress in clinical trials for Alzheimer's treatments, and the outlook for its multiple sclerosis Tecfidera drug.

  • Biotechs stick it to stocks Monday, 27 Apr 2015 | 4:30 PM ET
    Medical injection

    Biotech is getting roughed up, after leading the market's gains this year.

  • What's wrong with healthcare and biotech? Monday, 27 Apr 2015 | 3:32 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Biotech, which has been a market leader all year, is weak, with both the market-cap weighted IBB and equal weighted XBI down roughly 4 percent each.

  • Traders work on the floor of the New York Stock Exchange.

    U.S. stocks closed higher on Friday, with the Nasdaq setting another record as investors cheered major earnings reports.

  • April 24- Slowing sales of Biogen Inc's key oral multiple sclerosis drug Tecfidera and a delay in a data readout for its keenly watched Alzheimer's drug sent the company's stock down as much as 8 percent on Friday. If Tecfidera's U.S. trajectory does not improve, Biogen's revenue growth may come in at the lower end of its previously issued forecast, Chief...

  • April 24- Sales of Biogen Inc's key oral multiple sclerosis drug Tecfidera fell on a sequential basis in the first quarter for the first time since its launch in 2013, sending the company's stock down as much as 8 percent on Friday. If Tecfidera's U.S. trajectory does not improve, Biogen's revenue growth may come in at the lower end of its previously issued...

  • Wall Street eyes data, Greece meeting Friday, 24 Apr 2015 | 9:05 AM ET
    An image of Mark Zuckerberg, chief executive officer of Facebook Inc., left, with Robert Greifeld, chief executive officer of Nasdaq OMX Group, right, is projected at the Nasdaq MarketSite in New York, May 18, 2012.

    U.S. stock index futures indicated a higher open on Friday, as investors cheered a record Nasdaq close spurred by positive earnings.

  • Early movers: BIIB, XRX, MSFT, AMZN, SBUX & more Friday, 24 Apr 2015 | 8:09 AM ET
    Traders work the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Tecfidera raked in sales of $824.9 million in the first quarter ended March 31, compared with $506 million a year earlier, but missed consensus projections of about $931 million, according to Deutsche Bank. We saw moderating patient growth of Tecfidera in the United States and Germany, Chief Executive George Scangos said in a statement. Net income attributable...

  • April 24- Biogen Inc reported a 71 percent rise in quarterly profit, driven by strong demand for its top-selling oral multiple sclerosis drug, Tecfidera. The U.S. biotechnology company's net profit soared to $822.5 million, or $3.49 per share, in the first quarter ended March 31, from $480 million, or $2.02 per share, a year earlier. Excluding items, Biogen earned...

  • Wall Street looks to finish week strong Friday, 24 Apr 2015 | 6:10 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Big tech names will dominate market movements on Friday, with continuation of Greece debt talks and just one economic data point expected.

  • Traders focus on tech, but keep one eye on Greece Thursday, 23 Apr 2015 | 6:42 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Big tech names will dominate market movements on Friday, with continuation of Greece debt talks and just one economic data point expected.

  • Four trades to go before the closing bell Thursday, 23 Apr 2015 | 2:53 PM ET

    The "Halftime Report" traders give their top trades for the second half of the trading day.